FDA Emphasizes Pathogen ID In Complicated Intra-Abdominal Infection Guidance
The agency checked another box on the list of guidances anticipated by developers of antibiotic drugs with the Oct. 1 release of a draft guidance on treatments for complicated intra-abdominal infections.
You may also be interested in...
FDA is less prescriptive on a variety of clinical development options, including inclusion and exclusion criteria, dosing, study comparators and safety in final document on antibiotics for complicated intra-abdominal infection.
Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.
Using the ICAAC annual meeting as a platform, MedImmune execs explain efforts to reinvigorate the company’s infectious disease pipeline. Early data suggest a possible supporting role for monoclonal antibody candidates in preventing and treating bacterial infections.